OPGN - CONSENSUS CO - OpGen, Inc.

OpGen, Inc. (OPGN) faces the threat of liquidation due to stringent regulatory oversight and the slow implementation of tests in clinics. The business has lost its ability to generate profit, and its market resilience is in critical decline. The company relies on third-party laboratories, lacking its own manufacturing plants, while the metric stands at . This price chart on the GURU.Markets platform clearly demonstrates the current state of this drug developer.

This indicator compares the asset's intrinsic value with average market expectations, allowing for an assessment of business maturity and the predictability of its cash flows. By analyzing the consensus target of the analytical coverage, an investor identifies capital stagnation, which in the case of OpGen, Inc. (OPGN) is confirmed by a critical liquidity shortage, the loss of B2B clients, and the forced sale of intellectual assets as part of legal proceedings.